{"id":992560,"date":"2026-08-10T07:04:49","date_gmt":"2026-08-10T11:04:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/"},"modified":"2026-08-10T07:04:49","modified_gmt":"2026-08-10T11:04:49","slug":"bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/","title":{"rendered":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development<\/b><\/p>\n<p class=\"bwalignc\"><b><i>MIMETAS\u2019 unique organ-on-a-chip and human tissue models complement Bruker\u2019s multiomics, NMR, spatial biology and preclinical imaging solutions<\/i><\/b><\/p>\n<p>LEIDEN, The Netherlands&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54586570&amp;newsitemid=20260810455540&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=49a356e42089eb52a07e30b3a40e29c1\">Bruker Corporation<\/a> (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker\u2019s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg\" alt=\"MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing human-relevant tissues in a high-throughput plate format. The OrganoPlate\u00ae platform enables advanced disease modeling, drug testing, and safety assessment. Shown clockwise from the bottom right: immune cell migration from a blood vessel, a vascularized liver model, a gut tubule, a colon organoid-derived tubule, and a vascularized lung model\" \/><\/p>\n<p style=\"font-size:85%\">MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing human-relevant tissues in a high-throughput plate format. The OrganoPlate\u00ae platform enables advanced disease modeling, drug testing, and safety assessment. Shown clockwise from the bottom right: immune cell migration from a blood vessel, a vascularized liver model, a gut tubule, a colon organoid-derived tubule, and a vascularized lung model<\/p>\n<\/div>\n<p>\nMIMETAS develops scalable organ-on-a-chip platforms and human tissue models that allow researchers to study disease mechanisms and compound responses in perfused, biologically relevant systems. Its <i>OrganoPlate<\/i>\u00ae platform combines a standard microtiter-plate format with membrane-free microfluidic tissue cultures, supporting imaging, automated handling and higher-throughput research and development workflows. Bruker plans to combine these capabilities with its technologies in proteomics, metabolomics, NMR, preclinical imaging and spatial biology.<\/p>\n<p>\n\u201cHuman physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates,\u201d said Frank H. Laukien, President and CEO of Bruker Corporation. \u201cThe unique MIMETAS organ-on-a-chip platforms complement Bruker\u2019s capabilities in multiomics, spatial biology and preclinical imaging. We believe that humanized Microphysiological Systems, or NAMs, have a bright future, and will be increasingly adopted in drug discovery, development and preclinical testing.\u201d<\/p>\n<p>\nThe MIMETAS portfolio includes the <i>OrganoPlate<\/i> platform for organ-on-a-chip research, <i>OrganoReady<\/i>\u00ae tissue and organoid products, supporting instruments and contract research services. The companies plan to develop integrated product and service workflows that connect these human model systems with Bruker technologies and services for molecular and cellular characterization.<\/p>\n<p>\nA Senior Scientific Director at a global pharmaceutical company commented: \u201cThe OrganoReady Colon Organoid Model combined with the OrganoTEER\u00ae system has become fully integrated into our toxicity-testing workflow. The platform fits seamlessly into our routine screening and supports consistent, reproducible data generation.\u201d<\/p>\n<p>\n\u201cJoining Bruker creates opportunities to scale our platforms and make advanced human tissue models available to more researchers worldwide,\u201d said Paul Vulto and Jos Joore, co-founders and co-CEOs of MIMETAS. \u201cBy combining our <i>OrganoPlate<\/i> and <i>OrganoReady<\/i> solutions with Bruker\u2019s molecular and cellular characterization technologies, we aim to offer more integrated workflows for disease research, compound evaluation and drug development.\u201d<\/p>\n<p>\nBruker and MIMETAS serve pharmaceutical and biotechnology researchers with complementary technologies. The combination is expected to connect advanced human tissue models with molecular, cellular and spatial characterization, supporting evidence generation for disease research, drug-development decisions and AI foundation models.<\/p>\n<p>\nFinancial details of the transaction were not disclosed. MIMETAS will continue to operate under its established brand and management.<\/p>\n<p><b>About Bruker Corporation \u2013 Leader of the Post-Genomic Era <\/b>(Nasdaq: BRKR)<br \/>\n<br \/>Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker\u2019s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54586570&amp;newsitemid=20260810455540&amp;lan=en-US&amp;anchor=www.bruker.com&amp;index=2&amp;md5=b70d560b53c6b87b12d59a146f6c7d57\">www.bruker.com<\/a>.<\/p>\n<p><b>About MIMETAS:<br \/>\n<br \/><\/b>MIMETAS is a global leader in human organ-on-a-chip solutions for drug discovery and development. Through its proprietary OrganoPlate\u00ae platform, the company provides predictive human tissue and disease models that help pharmaceutical and biotechnology companies improve decision making across the R&amp;D pipeline, from target validation and disease understanding to efficacy and safety assessment. By combining human-relevant biology, scalable laboratory workflows and deep application expertise, MIMETAS enables customers to generate actionable data that improves clinical translation, accelerates development timelines and supports the transition away from animal testing. The company&#8217;s solutions are used by many of the world&#8217;s leading life science organizations to address critical challenges in drug discovery, toxicology, and selection. With operations in North America, Europe and Asia, MIMETAS is committed to advancing human-centric research through innovative products, contract research services and New Approach Methodologies that deliver better science and better outcomes for patients.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260810455540r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Joe Kostka<br \/>\n<br \/>Director, Investor Relations &amp; Corporate Development<br \/>\n<br \/>Bruker Corporation<br \/>\n<br \/>T: +1 978 313-5800<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:Investor.Relations@bruker.com\">Investor.Relations@bruker.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Markus Ziegler<br \/>\n<br \/>Sr. Director and Head of Group Marketing<br \/>\n<br \/>Bruker BioSpin<br \/>\n<br \/>T: +49 172 3733531<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:pr@bruker.com\">pr@bruker.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States Netherlands North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Health Technology General Health Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/3\/OrganoPlate.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing human-relevant tissues in a high-throughput plate format. The OrganoPlate\u00ae platform enables advanced disease modeling, drug testing, and safety assessment. Shown clockwise from the bottom right: immune cell migration from a blood vessel, a vascularized liver model, a gut tubule, a colon organoid-derived tubule, and a vascularized lung model<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/772973\/3\/Bruker_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development MIMETAS\u2019 unique organ-on-a-chip and human tissue models complement Bruker\u2019s multiomics, NMR, spatial biology and preclinical imaging solutions LEIDEN, The Netherlands&#8211;(BUSINESS WIRE)&#8211;Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker\u2019s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/ MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992560","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development MIMETAS\u2019 unique organ-on-a-chip and human tissue models complement Bruker\u2019s multiomics, NMR, spatial biology and preclinical imaging solutions LEIDEN, The Netherlands&#8211;(BUSINESS WIRE)&#8211;Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker\u2019s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/ MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing &hellip; Continue reading &quot;Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T11:04:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development\",\"datePublished\":\"2026-08-10T11:04:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/\"},\"wordCount\":952,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260810455540\\\/en\\\/2871912\\\/4\\\/OrganoPlate.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/\",\"name\":\"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260810455540\\\/en\\\/2871912\\\/4\\\/OrganoPlate.jpg\",\"datePublished\":\"2026-08-10T11:04:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260810455540\\\/en\\\/2871912\\\/4\\\/OrganoPlate.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260810455540\\\/en\\\/2871912\\\/4\\\/OrganoPlate.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/","og_locale":"en_US","og_type":"article","og_title":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development - Market Newsdesk","og_description":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development MIMETAS\u2019 unique organ-on-a-chip and human tissue models complement Bruker\u2019s multiomics, NMR, spatial biology and preclinical imaging solutions LEIDEN, The Netherlands&#8211;(BUSINESS WIRE)&#8211;Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker\u2019s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260810455540\/en\/ MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing &hellip; Continue reading \"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-10T11:04:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development","datePublished":"2026-08-10T11:04:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/"},"wordCount":952,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/","name":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg","datePublished":"2026-08-10T11:04:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260810455540\/en\/2871912\/4\/OrganoPlate.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-announces-majority-investment-in-mimetas-to-advance-human-physiology-relevant-drug-discovery-and-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992560"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992560\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}